Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Olfactory dysfunction in Parkinson's disease.

Z K Wszolek1, K Markopoulou

  • 1Department of Neurology, Mayo Clinic Jacksonville, FL 32224, USA.

Clinical Neuroscience (New York, N.Y.)
|April 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Partial loss of function of colony-stimulating factor 1 receptor in a patient with white matter abnormalities.

European journal of neurology·2018
Same author

Diagnostic criteria for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia due to CSF1R mutation.

European journal of neurology·2017
Same author

Atypical parkinsonian syndromes: a general neurologist's perspective.

European journal of neurology·2017
Same author

Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy.

Neuropathology and applied neurobiology·2016
Same author

Clinical and genetic characterization of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia associated with CSF1R mutation.

European journal of neurology·2016
Same author

Diagnostic Value of Brain Calcifications in Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia.

AJNR. American journal of neuroradiology·2016
Same journal

Cardiovascular autonomic dysfunction in parkinsonian patients.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Visuo-cognitive dysfunctions in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Gastrointestinal dysfunction in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Respiratory function in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Neurophysiology of sensorimotor integration in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Imaging of nonmotor symptoms in Parkinson syndromes.

Clinical neuroscience (New York, N.Y.)·2000
See all related articles

Olfactory dysfunction is an early non-motor symptom in Parkinson's disease (PD) and may help differentiate PD subtypes. This olfactory impairment is linked to neurodegeneration, not dopamine levels.

Area of Science:

  • Neuroscience
  • Neurology
  • Pathology

Background:

  • The olfactory system is significantly impacted in Parkinson's disease (PD), presenting as an early non-motor symptom.
  • Olfactory dysfunction in PD is independent of disease stage, duration, or treatment, but varies by subtype.

Purpose of the Study:

  • To investigate the role of olfactory dysfunction in differentiating Parkinson's disease (PD) from parkinsonism-plus syndromes (PPS).
  • To explore the relationship between olfactory impairment and other neurodegenerative diseases and normal aging.

Main Methods:

  • The study reviews existing literature on olfactory function in Parkinson's disease (PD), parkinsonism-plus syndromes (PPS), familial parkinsonism, Alzheimer's disease (AD), Huntington's disease (HD), and normal aging.
  • Analysis focuses on the characteristics and potential mechanisms of olfactory dysfunction in these conditions.

Related Experiment Videos

Main Results:

  • Olfactory dysfunction is a consistent early feature in typical Parkinson's disease (PD) but is milder or absent in most parkinsonism-plus syndromes (PPS), aiding differential diagnosis.
  • Impaired olfaction is also observed in familial parkinsonism, Alzheimer's disease (AD), Huntington's disease (HD), and normal aging.
  • Neuropathological changes in the olfactory system appear disease-specific, suggesting a central origin for olfactory dysfunction.

Conclusions:

  • Olfactory testing can be a valuable tool for distinguishing between typical Parkinson's disease (PD) and parkinsonism-plus syndromes (PPS).
  • The underlying cellular and molecular mechanisms of olfactory dysfunction in PD and other neurodegenerative diseases require further investigation.